PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer

Gordon C Wishart*†1,7, Elizabeth M Azzato†2,3, David C Greenberg4, Jem Rashbass4, Olive Kearins5, Gill Lawrence5, Carlos Caldas1,6,7 and Paul DP Pharoah2

Abstract

Introduction: The aim of this study was to develop and validate a prognostication model to predict overall and breast cancer specific survival for women treated for early breast cancer in the UK.

Methods: Using the Eastern Cancer Registration and Information Centre (ECRIC) dataset, information was collated for 5,694 women who had surgery for invasive breast cancer in East Anglia from 1999 to 2003. Breast cancer mortality models for oestrogen receptor (ER) positive and ER negative tumours were derived from these data using Cox proportional hazards, adjusting for prognostic factors and mode of cancer detection (symptomatic versus screen-detected). An external dataset of 5,468 patients from the West Midlands Cancer Intelligence Unit (WMCIU) was used for validation.

Results: Differences in overall actual and predicted mortality were <1% at eight years for ECRIC (18.9% vs. 19.0%) and WMCIU (17.5% vs. 18.3%) with area under receiver-operator-characteristic curves (AUC) of 0.81 and 0.79 respectively. Differences in breast cancer specific actual and predicted mortality were <1% at eight years for ECRIC (12.9% vs. 13.5%) and <1.5% at eight years for WMCIU (12.2% vs. 13.6%) with AUC of 0.84 and 0.82 respectively. Model calibration was good for both ER positive and negative models although the ER positive model provided better discrimination (AUC 0.82) than ER negative (AUC 0.75).

Conclusions: We have developed a prognostication model for early breast cancer based on UK cancer registry data that predicts breast cancer survival following surgery for invasive breast cancer and includes mode of detection for the first time. The model is well calibrated, provides a high degree of discrimination and has been validated in a second UK patient cohort.
based on individual NPI scores rather than the mean survival of the six groups previously described [5].

Adjuvant! is a web-based prognostication and treatment benefit tool for breast cancer that is now widely used in the UK to help clinicians and patients make decisions about adjuvant therapy. The mortality estimates used in Adjuvant! were based on 10-year observed overall survival (OS) of women aged 36 to 69 who were diagnosed between 1988 and 1992 and recorded in the Surveillance, Epidemiology and End Results (SEER) registry [6]. Breast cancer specific survival (BCSS) without adjuvant therapy was calculated based on estimates of the number of patients likely to have received systemic therapy and the risk reductions outlined in the Early Breast Cancer Trialists’ Collaborative Group [7,8]. Although these assumptions have now been validated in a population-based Canadian dataset [9] there has always been some uncertainty about how applicable the Adjuvant! model is to contemporary patients diagnosed and treated in the UK. A recent paper has shown that Adjuvant! overestimated the overall survival by 6% in a UK cohort of 1,065 women with early breast cancer treated in Oxford between 1986 and 1996 [10].

The primary aim of this study therefore was to develop a prognostication model to predict OS from a large cohort of UK women diagnosed in East Anglia from 1999 to 2003 using cancer registration and OS data recorded by the Eastern Cancer Registration and Information Centre (ECRIC). ECRIC provides near complete breast cancer registration for 10 hospitals in East Anglia as well as information on systemic treatment and mode of detection. A secondary aim of this study was to validate the model in a second UK cancer registry dataset to facilitate development of an online prognostication and treatment benefit tool for UK-based patients with early breast cancer.

Materials and methods
Study population
The primary analysis was based on data from patients with invasive breast cancer diagnosed in East Anglia, UK between 1999 and 2003 identified by ECRIC. ECRIC covers a catchment area population of approximately 5.5 million people and registers all malignant tumours occurring in people resident in East Anglia at the time of diagnosis. ECRIC also records prospectively demographic, pathologic, staging, general treatment and outcome information. Death certificate flagging through the Office of National Statistics provides the registries with notification of deaths. The lag times for this are a few weeks for cancer deaths and two months to a year for non-cancer deaths. In addition, ECRIC checked vital status by querying the National Health Service Strategic Tracing Service. Vital status was ascertained at the end of June 2008 and all analyses were censored on 31 December 2007 to allow for delay in reporting of vital status. Breast cancer specific mortality was defined as deaths where breast cancer was listed as the cause of death on Parts 1a, 1b, or 1c of the death certificate.

Information obtained from ECRIC included age at diagnosis, number of lymph nodes sampled and number of lymph nodes positive (categorised as 0, 1, 2 to 4, 5 to 9, and 10+ nodes positive), tumour size (categorised as <10 mm, 10 to 19 mm, 20 to 29 mm, 30 to 49 mm, 50+ mm), histological grade (I, II, III), oestrogen receptor (ER) status (positive or negative), mode of detection (screening vs. clinical), information on local therapy (wide local excision, mastectomy, radiotherapy), and type of adjuvant systemic therapy (chemotherapy, endocrine therapy, both). Exact chemotherapy regimens are unknown, but the majority of breast cancer patients in the ECRIC population received first or second generation chemotherapy during this time period. Patients who did not undergo surgery, patients with incomplete local therapy (wide local excision without radiotherapy) and patients with fewer than four nodes excised with a diagnosis of node-negative disease were excluded from the analyses, leaving a study population of 5,694 individuals (Table 1).

An independent validation dataset was comprised of women diagnosed with invasive breast cancer between 1999 and 2003 within the boundaries of the West Midlands Cancer Intelligence Unit (WMCIU). The geographic area served by WMCIU has a population of approximately 5.3 million individuals. Identical patient demographic information and study endpoints were retrieved from the WMCIU cancer registration database, with the same exclusions applied as for the ECRIC dataset. The total validation study population included 5,468 individuals (Table 1). As this was a large population-based study, with full anonymisation of all data, informed consent and ethical approval was not sought.

Prognostic model parameters
Breast cancer specific mortality and mortality from other causes (competing mortality) were modelled separately. For breast cancer specific mortality, a Cox proportional hazards model was used to estimate the hazard ratio associated with each prognostic factor. As the effect of ER status varies over time [11] ER negative and ER positive tumours were modelled separately. Nodal status, tumour grade and tumour size were modelled both as categorical variables and as ordinal variables. The models with ordinal variables fit the data better, and so these were chosen for the final models. Chemotherapy, endocrine therapy, and tumour detection by screening were treated as simple indicator variables. For the purposes of this study, screen-detected cancers were those discovered by screening mammography in the NHS Breast Screening Programme.
Table 1: Patient characteristics for model development (Eastern Cancer Registration and Information Centre-ECRIC) and validation (West Midlands Cancer Intelligence Unit-WMCIU) cohorts

|                        | ECRIC     | WMCIU     |
|------------------------|-----------|-----------|
| Total Number of Subjects | 5,694     | 5,468     |
| Total time at risk (years) | 31,904    | 25,917    |
| Median follow-up (years)* | 5.65 (0.04 to 8.00) | 4.85 (0.07 to 8.00) |
| Number of breast cancer deaths | 737       | 668       |
| Number of other deaths | 338       | 287       |
| Annual breast cancer mortality rate | 0.023 (0.021 to 0.025) | 0.026 (0.024 to 0.028) |
| Five-year breast cancer survival rate | 0.89 (0.88 to 0.90) | 0.88 (0.87 to 0.89) |
| Median age at diagnosis, years | 58 (23 to 95) | 58 (22 to 93) |

| Age, years | Number | Number |
|------------|--------|--------|
| <35        | 111    | 108    |
| 35 to 49   | 1,172  | 1,195  |
| 50 to 64   | 2,630  | 2,393  |
| 65 to 74   | 1,124  | 1,101  |
| 75+        | 657    | 671    |

| Nodal status | Number | Number |
|--------------|--------|--------|
| 0            | 3,532  | 3,184  |
| 1            | 741    | 746    |
| 2 to 4       | 806    | 792    |
| 5 to 9       | 380    | 451    |
| 10+          | 235    | 295    |

| Tumour size, mm | Number | Number |
|-----------------|--------|--------|
| <10             | 625    | 485    |
| 10 to 19        | 2,310  | 2,136  |
| 20 to 29        | 1,627  | 1,566  |
| 30 to 49        | 845    | 923    |
| 50+             | 287    | 358    |

| Grade | Number | Number |
|-------|--------|--------|
| I     | 1,005  | 1,017  |
| II    | 2,927  | 2,442  |
| III   | 1,762  | 2,009  |

| Oestrogen Receptor (ER) Status | Number | Number |
|-------------------------------|--------|--------|
| ER negative                   | 991    | 1,116  |
| ER positive                   | 4,703  | 4,352  |

| Adjuvant therapy | Number | Number |
|------------------|--------|--------|
| Chemotherapy     | 1,905  | 2,121  |
| Endocrine therapy| 4,268  | 2,406  |
| Combined chemoendocrine | 1,122 | 579    |

Screen detected
which at the time offered three-yearly mammography to women aged 50 to 64. In an exploratory analysis, age at diagnosis was included as a categorical variable in five age groups (<40, 40 to 49, 50 to 59, 60 to 69 and 70+) but these were not found to be significantly associated with breast specific mortality (data not shown) and age was excluded from subsequent models.

Competing mortality was modelled separately and adjusted for age at diagnosis. Exploration of the age-specific beta-coefficients suggested that the effect varied exponentially with age; the best fit model was age to the power of 2.38.

Model discrimination and calibration
We used the baseline survivor function from the ER negative and ER positive Cox proportional hazards models for breast cancer specific survival adjusted for the other prognostic factors to estimate the predicted number of deaths from breast cancer. Deaths from other causes were estimated from the baseline survivor function for competing mortality after adjusting for age. The total number of deaths at Years 5 and 8 after diagnosis was estimated by summing the breast-specific and competing mortality. Observed and predicted deaths were compared using a standard Chi-squared test. Model discrimination was evaluated by calculating the area under the receiver-operator-characteristic (ROC) curve (AUC) calculated for breast cancer specific and overall deaths at Year 8 past diagnosis. The ROC curve plots sensitivity against 1-specificity at different predicted risk thresholds. Model calibration was assessed using a simplified goodness-of-fit (GOF) method for the Cox proportional hazards model proposed by May and Hosmer [12] in which observed and model-based estimated deaths at Year 8 after diagnosis within deciles of risk score were compared. This provides a goodness of fit Chi-square test. As the baseline hazards and prognostic variable coefficients differed for ER positive and ER negative models, separate GOF tests were carried out for these models. In subgroup analyses, where numbers within deciles of risk score were small, quartiles of risk scores were used. Person-years lost were calculated by taking the area under the cumulative risk curve. Analyses were performed using STATA, version 9.2 (StataCorp, College Station, TX, USA).

Table 1: Patient characteristics for model development (Eastern Cancer Registration and Information Centre-ECRIC) and validation (West Midlands Cancer Intelligence Unit-WMCIU) cohorts (Continued)

|        | Yes | No |
|--------|-----|----|
|        | 1,621 | 28 | 1,256 | 23 |
|        | 4,073 | 72 | 4,212 | 77 |

* Follow-up censored at eight years
† Range of variable
‡ 95 CI

Table 2: Hazard ratios (95% CI) and model coefficients (standard errors) for prognostic factors included in the development models

| Prognostic Factor          | ER Positive Model | ER Negative Model |
|----------------------------|-------------------|------------------|
|                            | Hazard ratio      | 95% CI | Coefficient | SE | Hazard ratio | 95% CI | Coefficient | SE |
| Number Positive Nodes*     |                   |        |             |    |              |        |             |    |
| (0, 1, 2 to 4, 5 to 9, 10+) | 1.75              | 1.62 to 1.89   | 0.56        | 0.04 | 1.55        | 1.44 to 1.68 | 0.44 | 0.04 |
| Tumour Size, mm*           |                   |        |             |    |              |        |             |    |
| (<10, 10 to 19, 20 to 29, 30 to 49, 50+) | 1.43 | 1.30 to 1.58 | 0.36 | 0.05 | 1.45 | 1.29 to 1.63 | 0.37 | 0.06 |
| Tumour Grade*              |                   |        |             |    |              |        |             |    |
| (Low, Intermediate, High)  | 1.43              | 1.30 to 1.58  | 0.36 | 0.05 | 1.45 | 1.29 to 1.63 | 0.37 | 0.06 |
| Detection by Screening     | 0.70              | 0.53 to 0.92  | -0.36 | 0.14 | 0.86 | 0.56 to 1.32 | -0.15 | 0.22 |
| Chemotherapy               | 0.73              | 0.60 to 0.89  | -0.31 | 0.1 | 0.82 | 0.62 to 1.08 | -0.2 | 0.14 |
| Hormone therapy            | 0.95              | 0.74 to 1.23  | -0.05 | 0.13 | 1.43 | 1.09 to 1.89 | 0.36 | 0.14 |

* modeled as ordinal continuous
**Results**

**Initial model fit**

The ECRIC data set was used to derive the primary prognostic models for breast specific and competing mortality. Beta-coefficients and standard errors for each prognostic factor in both the ER negative and ER positive models are provided in Table 2. The estimated relative hazard associated with treatment with adjuvant hormone therapy was smaller than the published estimate based on randomised clinical trials [7,8] in women with ER positive tumours, and was associated with a poorer prognosis in women with ER negative tumours where no effect is expected based on clinical trial data. These differences are likely to represent bias due to clinical selection or patient non-compliance in the observational data.

As expected, this model was well calibrated. The model tended to over-predict mortality, but the difference between actual and predicted deaths was less than one percent at five and eight years after diagnosis (14.8 vs. 15.6 percent and 18.9 vs. 19.0 percent, respectively), differences that were not statistically significant ($P = 0.10$ and 0.83 respectively). There were 31,904 person-years of follow-up compared to 31,662 predicted. Model discrimination was also good - the calculated area under the ROC curve (AUC) for the overall model was 0.81 (SE 0.0074) (Table 3). Similarly, breast cancer specific actual and predicted mortality were within one percent at Years 5 and 8 past diagnosis (10.6 vs. 11.0 percent, $P = 0.28$ and 12.9 vs. 13.5 percent, $P = 0.26$, respectively; AUC = 0.84, SE = 0.008) (Additional file 1, Table S2). The ER positive and ER negative prognostic models were also well-calibrated overall and for all subgroups, and the goodness of fit tests suggest that the models fit well across different risk categories. The ER positive model provided better discrimination (AUC = 0.82, SE = 0.0111) than the ER negative model (AUC = 0.75, SE = 0.0171).

**Validation**

The WMCIU study population of 5,468 individuals was used for independent prognostic model validation. Over-

| Table 3: Overall actual and predicted mortality in Eastern Cancer Registration and Information Centre cohort |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|--------|--------|----------------|----------------|--------|--------|
| Group                                           | N      | %       | A     | P†     | Mortality Difference | A     | P†     | Mortality Difference | AUC   | SE    |
|-------------------------------------------------|--------|---------|-------|--------|----------------------|-------|--------|----------------------|-------|-------|
| **Year 5 deaths**                               |        |         |       |        |                      |       |        |                      |       |       |
| Total                                           | 5,694  | 100.00  | 841   | 890    | 0.86                  | 1,075 | 1,082  | 0.12                 | 0.81  | 0.007 |
| Age, years                                      |        |         |       |        |                      |       |        |                      |       |       |
| <35                                              | 111    | 1.95    | 28    | 23     | 4.5                  | 31    | 27     | 3.6                  | 0.83  | 0.044 |
| 35 to 49                                         | 1,172  | 20.58   | 150   | 171    | 1.79                 | 187   | 209    | 1.88                 | 0.81  | 0.017 |
| 50 to 64                                         | 2,630  | 46.19   | 270   | 289    | 0.72                 | 354   | 359    | 0.19                 | 0.80  | 0.013 |
| 65 to 74                                         | 1,124  | 19.74   | 176   | 191    | 1.33                 | 227   | 233    | 0.53                 | 0.79  | 0.019 |
| 75+                                              | 657    | 11.54   | 217   | 216    | 0.15                 | 276   | 254    | 3.35                 | 0.68  | 0.021 |
| Nodal status                                    |        |         |       |        |                      |       |        |                      |       |       |
| Negative                                        | 3,532  | 62.03   | 297   | 350    | 1.5                  | 408   | 433    | 0.71                 | 0.76  | 0.013 |
| Positive                                        | 2,162  | 37.97   | 544   | 541    | 0.14                 | 667   | 649    | 0.83                 | 0.80  | 0.010 |
| Tumour size, mm                                 |        |         |       |        |                      |       |        |                      |       |       |
| <10                                             | 625    | 10.98   | 30    | 39     | 1.44                 | 41    | 49     | 1.28                 | 0.75  | 0.038 |
| 10 to 19                                        | 2,310  | 40.57   | 194   | 222    | 1.21                 | 267   | 280    | 0.56                 | 0.75  | 0.017 |
| 20 to 29                                        | 1,627  | 28.57   | 277   | 283    | 0.37                 | 363   | 347    | 0.98                 | 0.79  | 0.013 |
| 30 to 49                                        | 845    | 14.84   | 148   | 226    | 1.3                  | 259   | 270    | 1.3                  | 0.76  | 0.018 |
| 50+                                             | 287    | 5.04    | 125   | 119    | 0.29                 | 145   | 136    | 3.14                 | 0.82  | 0.024 |
| Grade                                           |        |         |       |        |                      |       |        |                      |       |       |
| I                                               | 1,005  | 17.65   | 38    | 64     | 2.59                 | 55    | 82     | 2.69                 | 0.76  | 0.035 |
| II                                              | 2,927  | 51.40   | 331   | 357    | 0.89                 | 455   | 445    | 0.34                 | 0.77  | 0.013 |
| III                                             | 1,762  | 30.94   | 472   | 470    | 0.11                 | 565   | 555    | 0.57                 | 0.77  | 0.012 |
| Oestrogen Receptor (ER) Status                   |        |         |       |        |                      |       |        |                      |       |       |
| Negative                                        | 991    | 17.40   | 321   | 318    | 0.3                  | 364   | 353    | 1.11                 | 0.77  | 0.016 |
| Positive                                        | 4,703  | 82.60   | 520   | 572    | 1.11                 | 711   | 729    | 0.38                 | 0.80  | 0.009 |

* Number of deaths after censoring follow up at five and eight years after diagnosis.
† Predicted number of deaths rounded to nearest whole number.
all the model was well calibrated. The tendency to over-predict mortality was slightly worse than with the ECRIC data but the difference between actual and predicted mortality was still small (<2 percent) at five years past diagnosis (15.8 vs. 17.4 percent, \( P = 0.004 \)) and less than one percent at Year 8 past diagnosis (17.5 vs. 18.4 percent, \( P = 0.11 \)) (Table 4). There were 25,917 person-years of follow-up compared to 25,809 person-years predicted. The overall model AUC was calculated as 0.79 (SE = 0.0079). Breast cancer specific actual and predicted mortality were within two percent at Years 5 and 8 past diagnosis (11.0 vs. 12.6 percent and 12.2 vs. 13.6 percent, respectively; AUC = 0.82, SE = 0.0083) (Additional file 1, Table S1).

Overall, the ER positive and ER negative prognostic models were well-calibrated, although both models predict more breast cancer deaths than observed. The over-estimation was slightly greater for the ER negative model than the ER positive model. In ER negative disease, the Year 8 actual breast cancer mortality rate was 25.0 percent compared to 30.6 percent predicted; for ER positive tumours, Year 8 actual and predicted breast cancer mor-

| Group              | N     | %    | A   | p<sup>†</sup> | Mortality Difference | A   | p<sup>†</sup> | Mortality Difference | AUC  | SE  |
|--------------------|-------|------|-----|-------------|---------------------|-----|-------------|---------------------|------|-----|
| Total              | 5,468 | 100  | 862 | 950         | 1.61                | 955 | 1006        | 0.93                | 0.79 | 0.008 |
| Age, years         |       |      |     |             |                     |     |             |                     |      |      |
| <35                | 108   | 1.98 | 21  | 24          | 2.78                | 28  | 26          | 1.85                | 0.70 | 0.057 |
| 35 to 49           | 1,195 | 21.85| 153 | 185         | 2.68                | 175 | 201         | 2.18                | 0.79 | 0.018 |
| 50 to 64           | 2,393 | 43.76| 279 | 311         | 1.34                | 310 | 334         | 1                   | 0.80 | 0.013 |
| 65 to 74           | 1,101 | 20.14| 198 | 203         | 0.45                | 218 | 217         | 0.09                | 0.76 | 0.018 |
| 75+                | 671   | 12.27| 211 | 216         | 0.75                | 224 | 228         | 0.6                 | 0.72 | 0.021 |
| Nodal status       |       |      |     |             |                     |     |             |                     |      |      |
| Negative           | 3,184 | 58.23| 265 | 333         | 2.14                | 301 | 357         | 1.76                | 0.74 | 0.015 |
| Positive           | 2,284 | 41.77| 597 | 606         | 0.39                | 654 | 648         | 0.26                | 0.75 | 0.011 |
| Tumour size, mm    |       |      |     |             |                     |     |             |                     |      |      |
| <10                | 485   | 8.87 | 27  | 32          | 1.03                | 29  | 34          | 1.03                | 0.82 | 0.040 |
| 10 to 19           | 2,136 | 39.06| 173 | 216         | 2.01                | 196 | 233         | 1.73                | 0.76 | 0.018 |
| 20 to 29           | 1,566 | 28.64| 259 | 274         | 0.96                | 286 | 295         | 0.57                | 0.71 | 0.017 |
| 30 to 49           | 923   | 16.88| 257 | 258         | 0.11                | 272 | 276         | 0.43                | 0.72 | 0.018 |
| 50+                | 358   | 6.55 | 146 | 160         | 3.91                | 156 | 168         | 3.35                | 0.72 | 0.027 |
| Grade              |       |      |     |             |                     |     |             |                     |      |      |
| I                  | 1,017 | 18.6 | 66  | 67          | 0.1                 | 75  | 72          | 0.29                | 0.79 | 0.029 |
| II                 | 2,442 | 44.66| 314 | 318         | 0.16                | 359 | 344         | 0.61                | 0.77 | 0.013 |
| III                | 2,009 | 36.74| 482 | 554         | 3.58                | 521 | 589         | 3.38                | 0.75 | 0.012 |
| Oestrogen Receptor (ER) Status |       |      |     |             |                     |     |             |                     |      |      |
| Negative           | 1,116 | 20.41| 317 | 364         | 4.21                | 341 | 380         | 3.49                | 0.76 | 0.016 |
| Positive           | 4,352 | 79.59| 545 | 575         | 0.69                | 614 | 625         | 0.25                | 0.78 | 0.010 |

* Number of deaths after censoring follow up at five and eight years after diagnosis.
† Predicted number of deaths rounded to nearest whole number
tality were within one percent (8.9 vs. 9.2 percent). Overall model fit was good (GOF \(P\)-values > 0.05), although the fit was less good for some sub-groups. Specifically, for ER positive disease, the fit was not so good in women aged <35 years (GOF \(P\) = 0.01) and 35 to 49-year-old age category (\(P\) = 0.045). For ER negative disease, the model fit in node negative disease (GOF \(P\) = 0.03), 30 to 49 mm tumours size category (GOF \(P\) = 0.02) and high grade tumours (GOF \(P\) = 0.001) was not so good (Additional file 1, Table S2).

Model discrimination was also good, again being somewhat better for the ER positive model (AUC = 0.81, SE = 0.0111) than the ER negative model (AUC = 0.75, SE = 0.0169). There were no significant differences between the ROC curves generated with the ECRIC and WMCIU data (ER positive \(\chi^2 = 0.17, P = 0.68\), ER negative \(\chi^2 = 0.00, P = 0.95\) (Figure 1).

We also explored the overall and breast cancer specific mortality within T1N0 and T2N0 good prognosis subgroups where decisions regarding adjuvant therapy can be difficult and challenging (Additional file 1, Table S3). In the WMCIU population, 1,931 individuals were diagnosed with T1N0 tumours, while 1,182 individuals were diagnosed with T2N0 tumours. For T1N0 tumours, actual and predicted five- and eight-year overall mortality rates were within 2.1 percent (5.5 vs. 7.6 percent and 6.1 vs. 8.2 percent, respectively); actual and predicted five- and eight-year breast cancer specific mortality rates were within one percent (2.4 vs. 3.3 percent and 2.8 vs. 3.6 percent, respectively). For T2N0 tumours, actual and predicted five- and eight-year overall mortality was within 2.5 percent (11.7 vs. 14.1 percent and 13.5 vs. 15.2 percent, respectively); actual and predicted five- and eight-year breast cancer specific mortality was within one percent (7.9 vs. 8.7 percent and 9.1 vs. 9.4 percent, respectively).

Summary comparison of overview vs. model-derived therapy benefit estimates

Given the difference in the estimates of the effects of hormone therapy from the ECRIC dataset compared to published clinical trial data, we also fit models (constrained models) with the relative hazard of hormone therapy constrained to the published estimate from the 1998 overviews (relative hazard 0.68 for ER positive tumours). Under this constrained model, the coefficient estimates for the other prognostic factor coefficients were similar to the original, data-driven model (Additional file 1, Table S4). Performance of the constrained model was slightly poorer in the ECRIC data than the full data driven model (Table 5), but the difference between actual and predicted mortality at eight years and between actual and predicted person-years of follow-up was still small. In the WMCIU validation dataset, the constrained model performed bet-
than the full, data-driven model at predicting eight-year mortality and person-years of follow-up.

Finally, we tested the performance of models using the data derived coefficients for grade, node status, tumour size and mode of detection from the full and constrained models with the benefit estimates from the 1998 overviews (Table 5). First generation chemotherapy benefit estimates were applied in all these analyses. Again the models performed slightly poorer than the full, data-driven model in the ECRIC dataset, but somewhat better in the WMCIU validation dataset.

### Discussion

We have developed a prognostication model for early breast cancer based on data collated from a large number of patients within a single UK cancer registry. The model was validated using data from a second UK registry. As both model and validation datasets contain over 5,000 patients this model is likely to be predictive of overall survival for all women diagnosed with early breast cancer in the UK. The model was well calibrated and provides a high degree of discrimination across different prognostic groups. A particular strength of this project was the ability to access breast cancer specific mortality from ECRIC, based on death certificate reporting rather than being estimated from population data.

Accurate prediction of survival, and subsequent calculation of treatment benefit, has become increasingly sophisticated in the management of early breast cancer in the UK. Although the introduction of the NPI allowed risk stratification into five then six [4] prognostic groups, the original models provided survival estimates based on the average survival for each individual group. Furthermore, the model was based on treatment from a single institution where individual treatment bias may have an effect on overall survival. Despite this potential shortcoming, the NPI has been successfully validated in external datasets [3] and has now been further developed to include more individual survival prediction based on individual rather than group NPI scores [5].

The publication of the Adjuvant! prognostication and treatment benefit tool in 2001 led to widespread and early adoption in the UK. The web-based system allowed free access and was recognised as being user friendly for both clinicians as well as patients with breast cancer. Adjuvant! was seen to provide several advantages over and above the NPI including individual survival predictions and calculation of potential treatment benefits for that patient. The use of coloured bar charts to display this information facilitated the often difficult discussions surrounding systemic adjuvant therapies with patients and allowed the development of treatment thresholds for chemotherapy in individual breast units.

The Adjuvant! model is based on population data collected by the Surveillance, Epidemiology and End Results (SEER) registry [6]. Breast cancer specific survival (BCSS) without adjuvant therapy was calculated based on estimates of the number of patients likely to have received systemic therapy and the risk reductions outlined in the Early Breast Cancer Trialists’ Collaborative Group [7,8].
In contrast, systemic therapy was recorded for all patients used to generate this model, as well as breast cancer specific mortality. Breast cancer registration is close to 100 percent for both SEER and ECRIC data across specific geographic regions. This may limit their generalisability, but the good performance of the model based on ECRIC data in an independent dataset from a different region of the UK and validation of Adjuvant! using data from a population registry from Canada [9] suggests that this is not likely to be a significant problem.

A key aim that underpinned development of this model was to develop a prognostication and treatment benefit tool that benefited from the many attributes of the Adjuvant! model but which was specifically tailored to the UK population. UK cancer registries have near complete prospective data collection on breast cancer registration, pathological features, treatment and death notification. The ECRIC data used in this study included all female breast cancer cases that were treated surgically and were fully characterised for mode of detection, tumour size and grade, lymph node and ER status and details of adjuvant therapy. ECRIC collects data from more than 10 hospitals in East Anglia including only two teaching hospitals with strong research activity. As a result the data collected by ECRIC are likely to be representative of the UK as a whole and reflect good practise rather than best practise and was an ideal data source on which to base the initial model.

In addition, the success of the NHS Breast Screening Programme in the UK has meant that there has been a shift to better prognostic groups at diagnosis than previously. Two recent papers, have suggested that screen detection confers an additional survival benefit beyond stage shift and reduces the risk of systemic recurrence when compared with symptomatic cancers of a similar stage [13,14]. Although the majority of the survival advantage associated with breast screening can be explained by this shift to an earlier stage at diagnosis, recent evidence suggests that approximately 25 percent of the survival advantage is still unexplained [15]. Introduction of mode of detection (screen-detected versus symptomatic) was therefore a key requirement for this model, as was adjustment of the nodal status groups with creation of a single node positive group. The inclusion of a group with a single positive node will allow these patients to have more accurate survival prediction than previously, as prognosis in Adjuvant! is based on the average of the one to three node positive group.

The model performs well across all prognostic groups in the development (ECRIC) dataset except in patients ≥75 years old, where the predicted mortality at Year 8 past diagnosis was less than observed (250 predicted vs. 276 actual deaths). This was also seen in the validation (WMCIU) data. In these data the model also predicted a more favourable outcome than observed for low grade tumours and a less favourable outcome than observed for high grade and ER negative tumours.

A key decision, when considering the application of this model as a predictor of treatment benefit, is whether to use the data-derived coefficients for hormone therapy or chemotherapy or the benefit estimates from published overview data [7,8]. The application of the overview estimates to the full model was a strong predictor of both eight-year mortality and person-years follow-up in the WMCIU validation dataset and has the advantage of allowing regular updates as further overview results are published.

**Conclusions**

In conclusion we have developed a prognostication model for early breast cancer based on data from a UK cancer registry that has included mode of detection for the first time. The model is well calibrated, provides a high degree of discrimination and has been validated in a second UK patient cohort. This model, together with application of published relative risk reductions for systemic therapy, will underpin a new web-based prognostication and treatment benefit tool for early breast cancer in the UK.

**Additional material**

**Abbreviations**

AUC: area under ROC curve; BCSS: breast cancer specific survival; ECRIC: Eastern Cancer Registration and Information Centre; ER: oestrogen receptor; GOF: goodness-of-fit; NPI: Nottingham Prognostic Index; OS: overall survival; ROC: receiver-operator characteristic; SEER: Surveillance, Epidemiology and End Results; WMCIU: West Midland Cancer Intelligence Unit.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

GCM conceived of the project and participated in the design, analysis and writing of the manuscript. EMA participated in the design, statistical analysis and writing of the manuscript. PDPP participated in the design, statistical analysis and writing of the study. DCG participated in the design, data acquisition, analysis and writing of the manuscript. JR participated in the design and writing of the manuscript. OK participated in the data acquisition and writing of the man-
Acknowledgements

This project was funded by an unrestricted educational grant from Pfizer Limited. Pfizer Limited had no involvement in the data collection, analysis, data interpretation, writing of the manuscript or the decision to submit this paper for publication. GCW & CC receive research funding from the Cambridge NIHR Biomedical Research Centre. PDDP is a Senior Clinical Research Fellow of Cancer Research UK. EMA is supported by the National Cancer Institute and the NIHR-Cambridge Graduate Partnership Program.

Author Details

1. Cambridge Breast Unit, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 2QO, UK
2. Strangeways Research Laboratory, Department of Oncology, University of Cambridge, Worts Causeway, Cambridge CB1 8RN, UK
3. Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
4. Eastern Cancer Registration and Information Centre (ECRIC), Unit C, Mague Court, Shelford Bottom, Hinton Way, Cambridge CB2 2AD, UK
5. West Midlands Cancer Intelligence Unit, Public Health Building, The University of Birmingham, Birmingham, B15 2TT, UK
6. Department of Oncology, University of Cambridge, and Functional Breast Cancer Genomics Laboratory, Cancer Research UK Cambridge Research Institute, Li Ka-Shing Centre, Robinson Way, Cambridge CB2 0RE, UK and
7. National Institute of Health Research (NIHR) Cambridge Biomedical Research Centre, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 2QO, UK

Received: 19 September 2009 Revisions Requested: 10 December 2009 Revised: 26 December 2009 Accepted: 6 January 2010 Published: 6 January 2010

References

1. Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC: A prognostic index in primary breast cancer. Br J Cancer 1982, 45:361-366.
2. Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP, Blamey RW, Haybittle JL: Confirmation of a prognostic index in primary breast cancer. Br J Cancer 1987, 56:489-492.
3. D’Eredita G, Giardina C, Martellotta M, Natale T, Ferrarese F: Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long term follow-up that were treated in a single institution. Eur J Cancer 2001, 37:591-596.
4. Blamey RW, Ellis IO, Pinder SE, Lee AH, Macmillan RD, Morgan DA, Robertson JF, Mitchell MJ, Ball GR, Haybittle JL, Elston CW: Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur J Cancer 2007, 43:1548-1555.
5. Blamey RW, Pinder SE, Ball GR, Ellis IO, Elston CW, Mitchell MJ, Haybittle JL: Reading the prognosis of the individual with breast cancer. Eur J Cancer 2007, 43:1545-1547.
6. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HI: Computer Program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001, 19:980-991.
7. Early Breast Cancer Trialists’ Collaborative Group: Tamoxifen for early breast cancer: An overview of randomized trials. Lancet 1998, 351:1451-1467.
8. Early Breast Cancer Trialists’ Collaborative Group: Polychemotherapy for early breast cancer: An overview of randomized trials. Lancet 1998, 352:930-942.
9. Olliveto IA, Bajak CD, Ravdin PM, Speers CH, Goldman AJ, Norris RD, Davis GJ, Chia SK, Gelmon KA: Population-based validation of the prognostic model Adjuvant! for early breast cancer. J Clin Oncol 2005, 23:2716-2725.
10. Campbell HE, Taylor MA, Harris AL, Gray AM: An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom. Br J Cancer 2009, 101:1074-1084.

11. Azzato EM, Greenberg D, Shah M, Blows F, Driver KE, Caporaso NE, Pharoah PDP: Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates? Br J Cancer 2009, 100:1806-1811.
12. May S, Hosmer DW: A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model. Lifetime Data Analysis 1998, 4:109-120.
13. Joensuu H, Lehtimaki T, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, Aittila A, Lundin M, Isola J, Lundin J: Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 2004, 292:1064-1073.
14. Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA: Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 2005, 97:1195-1203.
15. Wishart GC, Greenberg DC, Britton PD, Chou P, Brown CH, Purushotham AD, Duffy SW: Screen-detected versus symptomatic breast cancer: is improved survival due to stage migration alone? Br J Cancer 2008, 98:1741-1744.